# Institut Curie

**Type:** Institutions  
**Canonical URL:** https://scholariq.org/institutions/institut-curie/

## Facts

| Field | Value |
| --- | --- |
| Avg h-index | 76.7 |
| Citations | 4,850,179 |
| City | Paris |
| Country | FR |
| Description | Institut Curie is a research organisation in Paris, FR. OpenAlex records 33,197 works and 4,850,179 citations for it. 5,630 researchers list it as their most recent affiliation. |
| Homepage | http://www.institut-curie.org/ |
| OpenAlex ID | https://openalex.org/I80043 |
| Region | Île-de-France |
| Researchers | 5,630 |
| ROR ID | https://ror.org/04t0gwh46 |
| Type | nonprofit |
| Works | 33,197 |

## University papers

Showing 12 of 22.

- [Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.](https://scholariq.org/papers/polychemotherapy-for-early-breast-cancer-an-overview-of-the-randomised-trials/)
- [70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer](https://scholariq.org/papers/70-gene-signature-as-an-aid-to-treatment-decisions-in-early-stage-breast-cancer/)
- [New driver mutations in non-small-cell lung cancer](https://scholariq.org/papers/new-driver-mutations-in-non-small-cell-lung-cancer/)
- [Amivantamab in EGFR Exon 20 Insertion–Mutated Non–Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study](https://scholariq.org/papers/amivantamab-in-egfr-exon-20-insertion-mutated-non-small-cell-lung-cancer/)
- [The 2015 World Health Organization Classification of Tumors of the Thymus: Continuity and Changes](https://scholariq.org/papers/the-2015-world-health-organization-classification-of-tumors-of-the-thymus/)
- [Deep learning-based classification of mesothelioma improves prediction of patient outcome](https://scholariq.org/papers/deep-learning-based-classification-of-mesothelioma-improves-prediction-of/)
- [Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients](https://scholariq.org/papers/immune-checkpoint-inhibitors-associated-with-interstitial-lung-disease-in-cancer/)
- [Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study](https://scholariq.org/papers/amivantamab-plus-chemotherapy-with-and-without-lazertinib-in-egfr-mutant/)
- [Amivantamab plus Lazertinib in Previously Untreated <i>EGFR</i> -Mutated Advanced NSCLC](https://scholariq.org/papers/amivantamab-plus-lazertinib-in-previously-untreated-i-egfr-i-mutated-advanced/)
- [Amivantamab plus Chemotherapy in NSCLC with <i>EGFR</i> Exon 20 Insertions](https://scholariq.org/papers/amivantamab-plus-chemotherapy-in-nsclc-with-i-egfr-i-exon-20-insertions/)
- [Randomized Phase III Placebo-Controlled Trial of Letrozole Plus Oral Temsirolimus As First-Line Endocrine Therapy in Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer](https://scholariq.org/papers/randomized-phase-iii-placebo-controlled-trial-of-letrozole-plus-oral/)
- [Treatment Characteristics and Real-World Progression-Free Survival in Patients With Unresectable Stage III NSCLC Who Received Durvalumab After Chemoradiotherapy: Findings From the PACIFIC-R Study](https://scholariq.org/papers/treatment-characteristics-and-real-world-progression-free-survival-in-patients/)

## University researchers

- [Nicolas Girard](https://scholariq.org/researchers/nicolas-girard/)

## University top topics

Showing 8 of 25.

- [Breast Cancer Treatment Studies](https://scholariq.org/topics/breast-cancer-treatment-studies/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)
- [DNA Repair Mechanisms](https://scholariq.org/topics/dna-repair-mechanisms/)
- [Sarcoma Diagnosis and Treatment](https://scholariq.org/topics/sarcoma-diagnosis-and-treatment/)
- [Microtubule and mitosis dynamics](https://scholariq.org/topics/microtubule-and-mitosis-dynamics/)
- [Cellular Mechanics and Interactions](https://scholariq.org/topics/cellular-mechanics-and-interactions/)
- [Genomics and Chromatin Dynamics](https://scholariq.org/topics/genomics-and-chromatin-dynamics/)
- [Cancer Treatment and Pharmacology](https://scholariq.org/topics/cancer-treatment-and-pharmacology/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.